Edwards Lifesciences Corporation

$89.78

-1.15%

2026-09-03 16:00:03 EDT-$1.04

Healthcare

Medical - Devices

NYSE

Active Trading

Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care ...

Price Action of EW

$89.78

-1.15%-$1.04

High—

Low—

52W High-6.8%

Rel. vol—

Interval

Range6.5h

Volume—SMA5SMA10

—

Edwards Lifesciences Corporation, headquartered in Irvine, California, is a leading global medical technology company focused on structural heart disease and critical care monitoring. Founded in 1958 by Miles 'Lowell' Edwards, the company has a rich history of innovation, starting with the development of the first commercially available artificial heart valve. ...Edwards Lifesciences Corporation, headquartered in Irvine, California, is a leading global medical technology company focused on structural heart disease and critical care monitoring. Founded in 1958 by Miles 'Lowell' Edwards, the company has a rich history of innovation, starting with the development of the first commercially available artificial heart valve. Today, Edwards is a pioneer in minimally invasive transcatheter heart valve replacement and repair, offering products like the SAPIEN platform for aortic valves and the PASCAL and Cardioband systems for mitral and tricuspid valve pathologies. Their surgical portfolio includes the INSPIRIS RESILIA aortic valve and the KONECT RESILIA valved conduit, alongside specialized tools like the HARPOON system for beating-heart mitral valve repair. In critical care, Edwards provides advanced hemodynamic monitoring systems and software such as the Acumen Hypotension Prediction Index, which helps clinicians anticipate and manage patient blood pressure risks. The company operates globally across the US, Europe, Japan, and other international markets, serving healthcare providers through both a direct sales force and distributor networks. With 16,000 employees, Edwards generated $6.5 billion in revenue for the trailing twelve months, exhibiting a gross profit margin of 78% and an operating margin of 28%. The company invests heavily in R&D (16.7% of revenue) to maintain its innovation edge. Financially, Edwards shows a strong balance sheet with a debt-to-equity ratio of just 0.066 and a current ratio of 4.52, reflecting robust liquidity. Its market capitalization stands at approximately $51.4 billion. Led by CEO Bernard J. Zovighian since May 2023, Edwards is committed to its mission of improving patient lives through breakthrough structural heart and critical care technologies, with a clear focus on expanding its transcatheter therapies and achieving worldwide adoption of its innovative products.ExpandCollapse

Founded

1958

Employees

16000

CEO

Bernard J. Zovighian

Full Name

Edwards Lifesciences Corporation

Sector

Healthcare

Industry

Medical - Devices

ROE

9.69%

Market Cap

$51.70B

Current Ratio

4.52

WACC

8.48%

ROIC

9.24%

Contact Information

https://www.edwards.com

949 250 2500

One Edwards Way, Irvine, CA 92614

Key Metrics of EW

Snapshot

Latest / TTM · 6 periods

Market Cap

$51.70B

ROCE

14.8%

EV / EBITDA

32.17x

+1.0% YoY

FCF Yield

2.8%

+0.1% YoY

Cash Conversion Cycle

287.6d

Current Ratio

4.52

Quick take

TTM —

Positive CCC

Financial Highlights of EW

Profitability trend

Latest / TTM · 6 periods

Gross Margin

78.0%

Net Margin

15.4%

P/E Ratio

51.64x

n/a

Debt / Equity

0.07

n/a

Current Ratio

4.52

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of EW

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $0.74 · Revenue $1.68B · 16 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $0.71 · Revenue $1.70B · 15 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $3.00 · Revenue $6.77B · 16 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $0.84 · Revenue $1.80B · 6 analysts

Recent history

Aug 4, 2026
Q2 FY2026 · Results reported
EPS $0.42 · Revenue $1.74B
View filing
May 6, 2026
Q1 FY2026 · Results reported
EPS $0.66 · Revenue $1.65B
View filing
Feb 25, 2026
FY2025 · Annual results
EPS $1.83 · Revenue $6.07B
View filing
Nov 5, 2025
Q3 FY2025 · Results reported
EPS $0.50 · Revenue $1.55B
View filing
Aug 6, 2025
Q2 FY2025 · Results reported
EPS $0.56 · Revenue $1.53B
View filing
May 6, 2025
Q1 FY2025 · Results reported
EPS $0.61 · Revenue $1.41B
View filing

Financial Statements of EW

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$6.1B	+11.5%	+5.6%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$1.1B	-74.3%	-36.5%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+78.1%	-1.7%	-0.8%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	+27.0%	+6.4%	-4.4%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	+17.7%	-76.9%	-39.8%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$1.3B	+360.5%	+2872.5%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	+22.0%	+312.8%	+2725.4%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	6.8%	-2.5%	-2.5%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	3.72x	-11.0%	+2.3%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$13.7B	+4.9%	+4.1%

Actual vs Estimate

A Dec 31Q Sep 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	1.83 vs 2.60	-29.5%	0.42 vs 0.74	-43.1%
Revenue Surprise	$6.1B vs $6.0B	+0.4%	$1.7B vs $1.7B	+3.9%

Insider Transactions of EW

Acquisitions (A)

Since Aug 11, 2026

Disposals (D)

Since Aug 11, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Aug 31, 2026	Dahl Andrew M.	officer: SVP, Corporate Controller	Common Stock	D	544	$91.06
Aug 28, 2026	Bruls Annette	officer: CVP, EMEACLA	Common Stock	D	2,644	$89.98
Aug 26, 2026	Chopra Daveen	officer: CVP, TMTT, Surgical & IHFM	Common Stock	A	31,800	$72.68
Aug 26, 2026	Chopra Daveen	officer: CVP, TMTT, Surgical & IHFM	Common Stock	D	1,154	$91.76
Aug 26, 2026	Chopra Daveen	officer: CVP, TMTT, Surgical & IHFM	Common Stock	D	30,646	$90.99

Earnings Call Transcript of EW

1 transcript segments

Q2 2026

Unknown Speaker

Operator : Greetings, and welcome to the Edwards Lifesciences Second Quarter 2026 Earnings Conference Call. As a reminder, this conference call is being recorded. It is now my pleasure to introduce Gerianne Sarte, Head of Investor Relations. Thank you. You may begin. Gerianne Sarte : Good afternoon, and thank you for joining us. With me on today's call is our CEO, Bernard Zovighian; and our CFO, Doretta Mistras. Also joining us for the Q&A portion of the call will be Dan Lippis, our Global Leader of TAVR; and Daveen Chopra, who has global responsibility for TMTT, Surgical and IHFM. After the close of regular trading, Edwards Lifesciences released second quarter 2026 financial results. During today's call, management will discuss the results included in the press release and accompanying financial schedules and then use the remaining time for Q&A. Please note that management will be making forward-looking statements that are based on estimates, assumptions and projections. These statements speak only as of the date on which they are made, and Edwards does not undertake any obligation to update them after today. Additionally, the statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. Factors that could cause these differences can be found in today's press release and Edwards' other SEC filings, all of which are available on the company's website at edwards.com. Unless otherwise noted, our commentary on sales growth refers to underlying sales growth, which is defined in the financial results press release issued earlier today. Reconciliations between GAAP and non-GAAP numbers mentioned during this call are also included in today's press release. Quarterly and full year growth rates refer to continuing operations. With that, I'll turn it over to Bernard for his comments. Bernard? Bernard Zovighian : Thank you, Gerianne, and welcome, everyone. Before we begin, I'd like to welcome Doretta to our first Edwards Life Sciences earnings call. Since joining in June, Doretta has quickly demonstrated her impact and valuable contribution as a member of the team, and we are pleased to have her leadership as we deliver on our patient-centered innovation strategy and our commitments to sustainable, distinguished performance. Let me begin with a high-level comment on our quarterly performance. We delivered stronger-than-expected second quarter sales growth of 12.5%. As Edwards continues to invest in new structural heart therapies and expand adoption globally, our results increasingly reflect the strength of our comprehensive portfolio with growth supported by multiple therapies across TAVR, mitral, tricuspid and surgical as well as meaningful contribution from each of our regions. Today, our company profile has evolved to include multiple strategic platforms across multiple regions that will support durable growth, giving us confidence in our target of …

Leadership Team of EW

10 executives

Name	Title	Compensation	Gender	Year Born	Status
Bernard J. Zovighian	Chief Executive Officer & Director	USD 3,788,122	Male	1968	Active
Theodora Mistras	Corporate Vice President & Chief Financial Officer	USD 1,845,590	Female	1982	Active
Annette Maria Bruls	Corporate Vice President of EMEA, Canada, & Latin America	USD 1,627,873	Female	1971	Active
Donald E. Bobo Jr.	Corporate Vice President of Strategy & Corporate Development	USD 1,595,262	Male	1962	Active
Daveen Chopra	Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies	USD 1,555,892	Male	1979	Active
Joseph Nuzzolese	Corporate Vice President of Global Operations & Quality	—	Male	—	Active
Mark D. Peterson	Corporate Vice President & General Counsel	—	Male	1963	Active
Todd Brinton FACC	Corporate VP of Advanced Innovation & Technology and Chief Scientific Officer	—	—	—	Active
Andrew Dahl	Principal Accounting Officer, Senior Vice President & Corporate Controller	—	Male	1978	Active
Snehashish Sarkar	Senior VP and Chief Information & Digital Officer	—	Male	1975	Active

Recent News of EW

GuruFocus8/26/2026Neutral

Is EW Overvalued? DCF Says Worth $53

On August 26, 2026, we delve into the DCF analysis for Edwards Lifesciences Corp (EW), a company that has seen a price performance of +12.4% over the past year

Defense World8/26/2026Neutral

Bank of Nova Scotia Takes Position in Edwards Lifesciences Corporation $EW

Bank of Nova Scotia bought a new position in Edwards Lifesciences Corporation (NYSE: EW) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 60,417 shares of the medical research company's stock, valued at approximately $5,465,000. Several other hedge funds also recently made

Defense World8/23/2026Neutral

37,702 Shares in Edwards Lifesciences Corporation $EW Bought by EP Wealth Advisors LLC

EP Wealth Advisors LLC bought a new position in Edwards Lifesciences Corporation (NYSE: EW) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 37,702 shares of the medical research company's stock, valued at approximately $3,410,000. Other institutional investors and hedge

Defense World8/22/2026Neutral

B. Metzler seel. Sohn & Co. AG Buys Shares of 41,753 Edwards Lifesciences Corporation $EW

B. Metzler seel. Sohn and Co. AG acquired a new position in Edwards Lifesciences Corporation (NYSE: EW) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 41,753 shares of the medical research company's stock, valued at approximately $3,777,000. Several other hedge

Defense World8/22/2026Neutral

Allworth Financial LP Takes Position in Edwards Lifesciences Corporation $EW

Allworth Financial LP bought a new position in Edwards Lifesciences Corporation (NYSE: EW) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 16,600 shares of the medical research company's stock, valued at approximately $1,502,000. A number of other hedge funds have also

Historical Employee Count of EW

Current

16,000

Change

+1.27%

Minimum

15,700

Maximum

19,800

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	16,000	10-K	Feb 25, 2026	View
Dec 31, 2024	15,800	10-K	Feb 28, 2025	View
Dec 31, 2023	19,800	10-K	Feb 12, 2024	View
Dec 31, 2022	17,300	10-K	Feb 13, 2023	View
Dec 31, 2021	15,700	10-K	Feb 14, 2022	View

Related stocksMedical - Devices

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Edwards Lifesciences Corporation